Sawai’s US Upsher-Smith business is now under new management as part of a “drastic restructuring” of the unit announced by the Japanese parent company, in the wake of disappointing annual results that included a major impairment loss of ¥68.8bn ($533m) linked to competitive pressures in US generics.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?